S. Murray Sherman to Retreatment
This is a "connection" page, showing publications S. Murray Sherman has written about Retreatment.
Connection Strength
0.112
-
A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer. Clin Cancer Res. 2016 Jan 01; 22(1):44-53.
Score: 0.112